The growing interest in hypoxia and HIFs in the context of cancer therapy has resulted in the development of many drugs that allow either HIF-1's chemical inhibition or activation (Nagle and Zhou, 2006; Masoud and Li, 2015), which could be very useful for the development of these strategies. This evidence concerns the gene HIF1A and cancer.